Found 699 none trials
A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
Subjects 18 years or older diagnosed with basal cell nevus syndrome (BCNS, also known as Gorlin syndrome). The main purpose of this study is to see if the study gel, which is applied to the face, reduces the number of new surgically eligible BCCs and learn more about the safety …
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA.
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum …
You are invited to take part in a research study for with the investigational drug, QR-110 (referred to as “the study drug”) for Leber's Congenital Amourosis . Currently there is no approved treatment for LCA10. The study drug is designed to repair the problem that causes LCA10. This may stop …
